Mvasi is the first biosimilar approved for the treatment of multiple types of cancer. The is approved for the treatment of adult patients with colorectal, lung, brain, kidney and cervical cancers.
Common side effects of Mvasi include nose bleeds, headache, high blood pressure, inflammation of the nasal cavity, high levels of protein in the urine, taste alteration, dry skin, rectal bleeding, excessive tear production back pain and skin irritation.
Serious side effects of Mvasi include holes in or abnormal connection between two organs, blood clot formation, hypertension, problems in brain function or structure, high levels of protein in the urine and ovarian failure.
haleplushearty.blogspot.com
No comments:
Post a Comment